External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>In FY22, RemeGen recorded revenue of RMB768mn, including RMB738mn product sales from RC18 and RC48, compared to RMB131mn product sales in FY21.</li><li>The Company improved its product gross profit margin from 48.9% in 2021 to 63.4% in 2022.</li><li>The SG&amp;A expenses in FY22 were RMB713mn, +47.7% YoY, due to the significant expansion in salesforce and increasing marketing activities following the approvals of RC18 and RC48 in 1H21.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In FY22, RemeGen recorded revenue of RMB768mn, including RMB738mn product sales from RC18 and RC48, compared to RMB131mn product sales in FY21.The Company improved its product gross profit margin from 48.9% in 2021 to 63.4% in 2022.The SG&amp;A expenses in FY22 were RMB713mn, +47.7% YoY, due to the significant expansion in salesforce and increasing marketing activities following the approvals of RC18 and RC48 in 1H21.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) – Wide clinical studies to unlock global potential

<ul><li>A pioneer biopharma with rich innovative pipelines. RemeGen has developed a robust pipeline of more than 10 drugs/candidates, including 7 clinical-stage assets targeting over 20 indications. </li><li>Since its inception in 2008, RemeGen has transformed from a biotech company into a fully integrated biopharma with two innovative biological drugs launched in China, telitacicept (RC18) and disitamab vedotin (RC48). </li><li>The Company is one of the few Chinese biotech companies that have successfully marketed two internally developed innovative biological drugs.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

A pioneer biopharma with rich innovative pipelines. RemeGen has developed a robust pipeline of more than 10 drugs/candidates, including 7 clinical-stage assets targeting over 20 indications. Since its inception in 2008, RemeGen has transformed from a biotech company into a fully integrated biopharma with two innovative biological drugs launched in China, telitacicept (RC18) and disitamab vedotin (RC48). The Company is one of the few Chinese biotech companies that have successfully marketed two internally developed innovative biological drugs.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

RemeGen (9995 HK) – A pioneer biopharma in innovative ADC and fusion protein medicines

China

RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00